

האוניברסיטה העברית בירושלים  
THE HEBREW UNIVERSITY OF JERUSALEM



FACULTY OF MEDICINE הפקולטה לרפואה

RAPHAEL MECHOULAM, Ph.D.  
Member, Israel Academy of Science

פרופ' רפאל משולם  
חבר האקדמיה הישראלית למדעים

Mr Neil Kapp,  
ABcann  
Canada

Dear Neil

March 16, 2017

I have followed the development of cannabis for medical use for many years.

There is no doubt that it is very helpful in numerous diseases. However many physicians refrain from prescribing it – even in states where it is legal – as much of the cannabis available is not standardized, with the levels of constituents varying considerably. Hence I believe that the route followed by ABcann for standardized cannabis grown under strict conditions, leading to reproducible contents, will not only satisfy physicians but will also make possible clinical trials which will develop the evidence to transform how cannabis is perceived today in the pharmaceutical industry and the regulatory agencies.

We, and many other researchers, have noted that different ratios of constituents may be needed for specific diseases. Hence a physician should be able to prescribe exact types of medical marijuana. This can be done only if standard plants or extracts are available.

Sincerely yours

Prof. R. Mechoulam

Hebrew University, Medical Faculty, Institute for Drug Research, Ein Kerem campus,  
Jerusalem 91120, Israel  
Tel: (+) 972-2-6758634. Fax: (+) 972-2-6758073  
E-mail: mechou@cc.huji.ac.il